“2012 was a landmark year for Actelion. Through the successful trial with macitentan (Opsumit®) announced in April, we have demonstrated our ability to innovate at Actelion. With organizational discipline and a strong commitment to quality, our clear objective ahead is to translate that innovation into benefits for patients and long-term value for shareholders. Actelion is now at a very exciting stage in its development."

“In 2012, we have achieved the appropriate balance between attractive shareholder returns, investment in the business and a strong capital structure. We have delivered significant returns to shareholders through the continuation of the buyback program and we are proposing a 25 percent increase in dividend. At the same time we continue with the right level of investment in R&D. Actelion therefore remains on track to deliver on the short- to mid-term core earnings guidance announced at the time of our strategic review.”